Date: 2016-09-26
Type of information: Loan
Company: Oryzon Genomics (Spain)
Investors: undisclosed Spanish commercial banks
Amount: € 10.5 million + € 5.3 million
Funding type: loan
Planned used: These funds will be used to further advance Oryzon Genomics' clinical programs in Alzheimer’s disease and in cancer.
The company has currently two programs in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Oryzon started recently a phase 1 of its oral LSD1-MAOB dual inhibitor ORY-2001 in healthy subjects. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in 1H 2017.
Others: * On September 26, 2016, Oryzon Genomics, a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that it has closed a second tranche of Debt Funding round of € 5.3 Million ($ 5.9 Million). These proceeds come on top of the € 10.5 Million ($ 11.6 Million) raised in May.In total, Oryzon have raised more than € 32 Million ($ 35.5 Million) since July 2015. * On May 4, 2016, Oryzon Genomics has announced that it has closed a Debt Funding round of € 10.5 million ($ 12.1 million), completing this way a Global Funding since July 2015 of € 27 million ($ 31.1 million). The round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market.
Therapeutic area: Cancer - Oncology - Neurodegenerative diseases
